These discrepancies might be attributed to the several factors including different study designs, diverse study populations, different follow-up duration, and diverse definition of baseline CHD among studies, as well as the marked advances in medications for managing multi-factorial risks of CHD such as renin-angiotensin system blockers, statins and anti-platelet agents. This evidence concerns the gene REN and coronary artery disorder.